Who Should Not Take a GLP-1?
Jillian Foglesong Stabile, MD
Board-certified Family Medicine · Diplomate, ABOM · Reviewed Jun 5, 2026
A short list of conditions makes a GLP-1 a clear no. These are called contraindications. They are not a judgment about you. They are a safety filter built from clinical trial data and the drug labeling. A physician checks each one before writing anything. The firmest reasons involve thyroid cancer history, a known allergy to the medication, and pregnancy. Each has its own logic.
The short answer
GLP-1 medications are not right for everyone. Personal or family history of medullary thyroid carcinoma, MEN2, a serious allergy to the drug, and pregnancy are firm reasons a physician will not prescribe one. Other conditions call for caution and closer monitoring. A licensed clinician decides eligibility. This article is educational, not medical advice.
What you will learn
- The firm reasons a physician will not prescribe a GLP-1
- The conditions that call for extra caution and a closer look
- Why pregnancy and breastfeeding change the conversation
- Which medications and histories your prescriber asks about
- The questions worth bringing so the screening works in your favor
Chapter 01 · The firm stops
Some people should not take a GLP-1
The word contraindication means the drug is not for this person, based on their specific history. These are not soft suggestions. They are the lines that do not move, written into the prescribing label.
The labeling for GLP-1 medications carries a boxed warning, the strongest warning a drug can carry. In rodent studies, these medicines caused thyroid C-cell tumors. Whether that risk carries to humans is not settled. Because of that uncertainty, the labeling says these drugs should not be used by anyone with a personal or family history of medullary thyroid carcinoma (often shortened to MTC), or with a syndrome called Multiple Endocrine Neoplasia type 2, or MEN2.1, 2
So a prescriber asks about your thyroid history and your family's. If MTC or MEN2 is in the picture, a GLP-1 is off the table. This is not a maybe. It is a line that does not move.
If MTC or MEN2 runs in your family, tell your prescriber before anything else. That detail is the first filter.
A serious allergic reaction is the other firm stop. If you have had a known hypersensitivity reaction to semaglutide, tirzepatide, or any ingredient in the formulation, you should not take it again. A reaction like that is your body drawing its own bright line. Your prescriber will ask about past reactions to any GLP-1 and to the inactive ingredients too.
Firm contraindications
Personal or family history of medullary thyroid carcinoma (MTC) or MEN2; known serious allergy to the medication or its ingredients; pregnancy. These are reasons a physician will not prescribe a GLP-1. This is a clinical safety filter, not a judgment.
Chapter 02 · Closer look
Conditions that call for caution, not an automatic stop
Some histories do not rule out a GLP-1 outright, but they change the math. Here a physician weighs the benefit against the risk, sometimes orders extra checks, and watches you more closely if treatment goes ahead. Pancreatitis history and serious digestive disease lead this group. The decision is individual, and it belongs to a clinician who knows your full record.
GLP-1 labeling lists pancreatitis (an inflammation of the pancreas) as a known risk to watch. Trials excluded or closely monitored people with a prior history of it. If you have had pancreatitis before, your physician needs to know. It does not always mean no, but it means a careful look and a clear plan for what symptoms to report.1, 3
The same caution applies to a few digestive conditions. Severe gastroparesis (a stomach that already empties slowly) can be a poor match for a drug that slows stomach emptying further. Inflammatory bowel disease and other serious gut conditions warrant a closer read. None of this is something to sort out alone. It is exactly what the intake questions are for.
Two more groups deserve a mention. People with significant kidney concerns may need closer monitoring, partly because the nausea and fluid shifts early in treatment can stress the kidneys. And people with type 1 diabetes were generally not studied for weight loss in these trials, so that history calls for specialist input rather than a routine sign-off.
Caution is not the same as a hard stop. It means a physician reviews your history, sets a plan, and watches you closely. The decision is theirs to make with you.
Chapter 03 · Pregnancy
Pregnancy and breastfeeding change the conversation
GLP-1 medications are not recommended during pregnancy. The reason is straightforward: weight loss is not a goal during pregnancy, and there is not enough safety data to support using these drugs while pregnant. Guidance generally advises stopping a GLP-1 well before a planned pregnancy. A physician will ask, and will help you plan around it.
Tell your prescriber if you are pregnant or trying to conceive. The labeling advises discontinuing these medications if you become pregnant, and planning ahead if you intend to conceive.1 There is one more detail worth knowing. GLP-1s can slow stomach emptying, which may affect how well oral medications absorb, including some birth control pills. That is a real reason to discuss contraception openly during screening.4
Breastfeeding sits in a similar place. Because there is limited data on whether these drugs pass into breast milk, a clinician weighs it case by case. The honest answer today is that the conversation matters more than any blanket rule.
Chapter 04 · Medications
Your other medications are part of the picture
A GLP-1 does not act in isolation. Your prescriber reviews your full medication list and your other diagnoses because some combinations need adjusting and some need a second thought. This is routine, and it is one of the strongest arguments for getting a GLP-1 through a real clinical review rather than a shortcut.
| Category | Examples | What a physician does |
|---|---|---|
| Firm contraindication | Personal or family history of MTC; MEN2; serious allergy to the drug; pregnancy | Does not prescribe a GLP-1 |
| Use with caution | History of pancreatitis; gallbladder disease; severe gastroparesis; type 1 diabetes; diabetic retinopathy history | Weighs benefit vs. risk, may add monitoring, decides with you |
| Needs coordination | Insulin or sulfonylurea use; oral medications needing steady absorption; some birth control | Reviews and adjusts the wider plan |
| Standard screening for everyone | Full history, current medications, kidney and thyroid questions, pregnancy status | Confirms a GLP-1 is appropriate before prescribing |
This table is educational, not a self-screen. Only a licensed clinician can decide whether a GLP-1 is right for you. Swipe to see the full table on a phone.
Insulin and sulfonylureas are a specific example. Both lower blood sugar. Adding a GLP-1 to that regimen can compound the effect, so doses may need to change. Oral medications that depend on a steady absorption rate can also be affected by slowed stomach emptying. The medications that come up most often in screening are the ones that touch blood sugar or that need predictable absorption to work correctly.
The honest summary
No single factor decides alone. A physician builds a picture from your history, your family history, your medications, and your current health before writing anything. That picture is the screening. An article cannot replace it.
Chapter 05 · The standard
The standard worth demanding before anyone prescribes
Here is the part that protects you most. The single best safeguard against a wrong prescription is a provider who actually screens before they sell. Not a checkbox. A real clinical review of your history, your family history, your medications, and your pregnancy status, done by a licensed clinician who can say no when no is the right answer.
A good provider asks about MTC and MEN2 before you ever see a prescription. They ask about pancreatitis, prior allergic reactions, and what you are currently taking. They follow up when your dose changes. They are reachable if something feels wrong. A blanket yes for everyone is the warning sign, not the reassurance.
sipra is built around this standard. Every prospective patient goes through a physician-led intake that screens for every contraindication listed here. If the answer is no, the physician says so. That is what a trustworthy program looks like.
You opened this page wondering if you might be one of the people who should not take a GLP-1. The honest answer is that only a clinician can settle that, and the good ones want to. Bring your full history. Let the screening do its job.
Your next three steps
This article is educational and is not medical advice. It does not diagnose, recommend, clear, or rule out any individual for treatment. A licensed clinician decides eligibility.
- Gather your history. Write down any thyroid conditions in your family, past pancreatitis, current medications, and your pregnancy status. These are the questions a screening will ask.
- Find a real clinical review. Look for a program where a licensed physician reads your intake and can say no when the answer is no. That is the standard that keeps you safe.
- Ask all the questions. No concern is too small. If a prescriber is not interested in your history, that is a signal to keep looking.
Your safety is the point of the screening.
Lose weight with a plan made just for you
- Same-day doctor visits and prescriptions
- Semaglutide, tirzepatide & other GLP-1s
- FSA & HSA eligible with all plans
From$79/mo
+ Sipra membership*
*Price includes medication only. Active $99/mo Sipra membership required.
Frequently asked questions
Sources
- U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information, including the boxed warning on thyroid C-cell tumors. Accessed June 2026. accessdata.fda.gov
- U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. Accessed June 2026. accessdata.fda.gov
- American Gastroenterological Association / clinical reviews on GLP-1 receptor agonists and pancreatitis risk. 2025. gastro.org
- Cleveland Clinic. "GLP-1 Agonists: Contraindications and Who Should Not Take Them." Accessed June 2026. my.clevelandclinic.org
Trademark attribution. Wegovy® is a registered trademark of Novo Nordisk A/S. Zepbound® is a trademark of Eli Lilly and Company. sipra is not affiliated with or endorsed by these companies.
Medically reviewed by
Jillian Foglesong Stabile, MD, FAAFP, DABOM
Was this helpful?
Keep reading
Weight LossGLP-1 weight loss 101: how semaglutide and tirzepatide actually work
17 min read
Weight LossHow GLP-1 Treatment With sipra Works, Step by Step
16 min read
Weight LossThe Real Cost of GLP-1 Medication: Every Number Before Your Card Is Charged
16 min read
Weight LossBranded vs compounded GLP-1s: the real difference in 2026
9 min read
Weight LossGLP-1 Myths That Won't Die (and the Facts That Beat Them)
9 min read
Weight LossGLP-1 Side Effects and How to Manage Them, Week by Week
10 min read
Weight LossHow GLP-1s work in the body: the science of appetite and satiety
9 min read
Weight LossWhat 503A compounding means (and why your prescription is made for you)
11 min read